Published in J Infect Dis on October 15, 2010
ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog (2012) 1.60
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. PLoS Pathog (2016) 1.43
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol (2011) 0.93
Role of IL-21 and IL-21 receptor on B cells in HIV infection. Crit Rev Immunol (2012) 0.90
The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single Infection. PLoS Pathog (2015) 0.86
Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. PLoS Pathog (2013) 0.83
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology (2014) 0.83
Boosting vaccine efficacy the natural (killer) way. Trends Immunol (2015) 0.82
Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2015) 0.76
Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. EBioMedicine (2016) 0.76
A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One (2015) 0.76
A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products. Hum Gene Ther Methods (2016) 0.75
Broadly Neutralising Antibodies Display Superior Potential Over Non-Neutralising Antibodies in Preventing HIV-1 infection of Mucosal Tissue. J Virol (2016) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Fcgamma receptors as regulators of immune responses. Nat Rev Immunol (2008) 11.34
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Fc receptor but not complement binding is important in antibody protection against HIV. Nature (2007) 7.96
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 5.38
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov (2009) 3.66
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A (1994) 3.33
Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol (2001) 2.79
Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol (1997) 2.75
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol (2006) 2.41
The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol (2001) 2.38
Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog (2009) 2.29
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
B lymphocyte dysfunctions in HIV infection. Curr HIV Res (2004) 2.07
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Epstein-Barr virus and human diseases: recent advances in diagnosis. Clin Microbiol Rev (1988) 1.78
Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett (2002) 1.62
Vaginal microbicides: moving ahead after an unexpected setback. AIDS (2007) 1.56
Spectrum of morphologic changes of lymph nodes from patients with AIDS or AIDS-related complexes. Prog Allergy (1986) 1.53
Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. Nat Med (1998) 1.50
Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol (2001) 1.42
Signaling in transitional type 2 B cells is critical for peripheral B-cell development. Immunol Rev (2004) 1.34
Positive selection and lineage commitment during peripheral B-lymphocyte development. Immunol Rev (2004) 1.29
Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med (1989) 1.28
Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med (1988) 1.23
Analyzing antibody-Fc-receptor interactions. Methods Mol Biol (2008) 1.19
Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr (2004) 1.18
Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol (2005) 1.12
Glycosylation of antibody therapeutics: optimisation for purpose. Methods Mol Biol (2009) 0.90
Ultrastructural analysis of germinal centers in lymph nodes of patients with HIV-1-induced persistent generalized lymphadenopathy: evidence for persistence of infection. Prog AIDS Pathol (1989) 0.90
Antibody responses in primary HIV-1 infection. Curr Opin HIV AIDS (2008) 0.85
Isolation of antigen-binding cells from unprimed mice. II. Evidence for monospecificity of antigen-binding cells. Eur J Immunol (1976) 0.82
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies (2005) 2.03
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol (2008) 1.69
Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J (2008) 1.55
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol (2011) 1.51
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
Polychromatic plots: graphical display of multidimensional data. Cytometry A (2008) 1.30
Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol (2011) 1.26
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol (2012) 1.24
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest (2014) 1.19
Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest (2015) 1.13
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med (2010) 1.11
Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. Retrovirology (2012) 1.10
Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr HIV Res (2013) 1.09
Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region. PLoS One (2009) 1.03
Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. J Clin Invest (2015) 0.98
Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol (2014) 0.94
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology (2009) 0.92
The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors. J Leukoc Biol (2013) 0.90
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. PLoS One (2012) 0.89
Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins (2015) 0.86
Predictive value of cerebrospinal fluid parameters in neonates with intraventricular drainage devices. J Neurosurg (2007) 0.86
Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol (2014) 0.85
Necrotizing fasciitis caused by Haemophilus influenzae type E in a 17-year-old girl with systemic lupus erythematosus. J Clin Rheumatol (2010) 0.83
T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. JCI Insight (2017) 0.82
Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. J Virol (2013) 0.81
Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer. Hum Antibodies (2012) 0.79
Antibodies for prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS (2015) 0.76
Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Genet Metab (2003) 0.76